Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,124
Out of 5,182 analysts
31
Total ratings
35.29%
Success rate
-24.31%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $28.73 | +46.19% | 1 | Nov 5, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $565.70 | -23.63% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $4.57 | +75.05% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $56 → $12 | $8.05 | +49.07% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $71.93 | -54.12% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.90 | +1,373.68% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $43.16 | -37.44% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.78 | +293.26% | 1 | Feb 10, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 14, 2022 | |
| NCNA NuCana | Maintains: Buy | $105,000 → $15,000 | $2.05 | +731,607.32% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.46 | +1,612.33% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $39.55 | -11.50% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $340.00 | -35.29% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $175.61 | +76.53% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $138.80 | -42.36% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $28.73
Upside: +46.19%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $565.70
Upside: -23.63%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $4.57
Upside: +75.05%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $56 → $12
Current: $8.05
Upside: +49.07%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $71.93
Upside: -54.12%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.90
Upside: +1,373.68%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $43.16
Upside: -37.44%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.78
Upside: +293.26%
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
NuCana
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $2.05
Upside: +731,607.32%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.46
Upside: +1,612.33%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $39.55
Upside: -11.50%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $340.00
Upside: -35.29%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $175.61
Upside: +76.53%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $138.80
Upside: -42.36%